Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

2.7 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

Natera has received 53.37% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote “Outperform” if you believe NTRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Miscellaneous

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

Natera (NASDAQ:NTRA) Frequently Asked Questions

How has Natera's stock been impacted by COVID-19 (Coronavirus)?

Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NTRA stock has increased by 30.7% and is now trading at $40.54. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Natera?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Natera.

When is Natera's next earnings date?

How were Natera's earnings last quarter?

Natera Inc (NASDAQ:NTRA) posted its earnings results on Wednesday, May, 6th. The medical research company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. The medical research company earned $94.01 million during the quarter, compared to the consensus estimate of $85.02 million. Natera had a negative net margin of 38.28% and a negative return on equity of 78.56%. Natera's revenue was up 40.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.54) earnings per share. View Natera's earnings history.

What guidance has Natera issued on next quarter's earnings?

Natera updated its first quarter 2020
Pre-Market earnings guidance on Monday, April, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $89-91 million, compared to the consensus revenue estimate of $79.45 million.

What price target have analysts set for NTRA?

8 equities research analysts have issued 12 month price targets for Natera's shares. Their forecasts range from $36.00 to $56.00. On average, they anticipate Natera's share price to reach $45.13 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price. View analysts' price targets for Natera.

What are Wall Street analysts saying about Natera stock?

Here are some recent quotes from research analysts about Natera stock:

2. Canaccord Genuity analysts commented, "We recently had the privilege of hosting Natera CEO Steve Chapman and CFO a well-attended fireside chat at the 39th in Boston. We continue to view NTRA as an undervalued cancer company trading at the multiple of an NIPT company. NTRA remains one of our favorite stocks and is one of our top picks for 2019. We reiterate our BUY rating and $38 PT. Signatera may be a game-changer in recurrence monitoring and MRD." (9/11/2019)

Has Natera been receiving favorable news coverage?

Media coverage about NTRA stock has been trending extremely negative on Sunday, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Natera earned a news impact score of -5.0 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutNatera.

When did Natera IPO?

(NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Which institutional investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Invesco Ltd., Fred Alger Management LLC, Federated Hermes Inc., Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, and Jennison Associates LLC. Company insiders that have sold Natera company stock in the last year include Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, and Steven Leonard Chapman. View insider buying and selling activity for Natera.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $40.54.

How big of a company is Natera?

Natera has a market capitalization of $3.19 billion and generates $302.33 million in revenue each year. The medical research company earns $-124,830,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Natera employs 1,039 workers across the globe.